Citations

Clear

3 citation(s) found for "Suarez, Luis".

Alveolar Hemorrhage in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Results of an International Randomized Controlled Trial (PEXIVAS)
Fussner, Lynn A. , Flores-Suárez, Luis Felipe , Cartin‐Ceba, Rodrigo , Specks, Ulrich , Cox, Gerard , Jayne, David , Merkel, Peter A. , Walsh, Michael , Moreland, Larry W. , Little, Mark A. , Johnson, David W. , Nachman, Patrick H. , Barratt, Jonathan , Bech, Jesper Nørgaard , Badve, Sunil V. , Jones, Rachel , Pavenski, Katerina , Cox, P Gerard , Jayne, David , Moreland, Larry W , Johnson, David W , Specks, Ulrich , Merkel, Peter A , Barratt, Jonathan , Birn, Henrik , Pavenski, Katerina

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | February 12, 2024 | Volume: 209 | Issue: 9 | Pages: 1141-1151

10.1164/rccm.202308-1426oc | PMID 38346237 Get It

Abstract Rationale Diffuse alveolar hemorrhage (DAH) is a life-threatening manifestation of antineutrophil cytoplasmic antibody–associated vasculitis (AAV). The PEXIVAS (Plasma Exchange and Glucocorticoids in Severe Antineutrophil Cytoplasmic Antibody–Associated Vasculitis) (NCT00987389) trial was the largest in AAV and the first to enroll participants with DAH requiring mechanical ventilation. Objectives Evaluate characteristics, treatment effects, and outcomes for patients with AAV with and without DAH. Methods PEXIVAS randomized 704 participants to plasma exchange (PLEX) or no-PLEX and reduced or standard-dose glucocorticoids (GC). DAH status was defined at enrollment as no-DAH, nonsevere, or severe (room air oxygen saturation of ≤ 85% as measured by pulse oximetry, or use of mechanical ventilation). Measurements and Main Results At enrollment, 191 (27.1%) participants had DAH (61 severe, including 29 ventilated) and were younger, more frequently relapsing, PR3 (proteinase 3)-ANCA positive, and had lower serum creatinine but were more frequently dialyzed than participants without DAH (n = 513; 72.9%). Among those with DAH, 8/95 (8.4%) receiving PLEX died within 1 year versus 15/96 (15.6%) with no-PLEX (hazard ratio, 0.52; confidence interval [CI], 0.21–1.24), whereas 13/96 (13.5%) receiving reduced GC died versus 10/95 (10.5%) with standard GC (hazard ratio, 1.33; CI, 0.57–3.13). When ventilated, ventilator-free days were similar with PLEX versus no-PLEX (medians, 25; interquartile range [IQR], 22–26 vs. 22–27) and fewer with reduced GC (median, 23; IQR, 20–25) versus standard GC (median, 26; IQR, 25–28). Treatment effects on mortality did not vary by presence or severity of DAH. Overall, 23/191 (12.0%) with DAH died within 1 year versus 34/513 (6.6%) without DAH. End-stage kidney disease and serious infections did not differ by DAH status or treatments. Conclusions Patients with AAV and DAH differ from those without DAH in multiple ways. Further data are required to confirm or refute a benefit of PLEX or GC dosing on mortality. Original clinical trial registered with www.clinicaltrials.gov (NCT00987389).
International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis
Moiseev, Sergey , Arimura, Yoshihiro , Blockmans, Daniël , Csernok, Elena , Damoiseaux, Jan , Emmi, Giacomo , Flores-Suárez, Luis Felipe , Jayne, David , Jennette, J. Charles , Little, Mark A. , Moosig, Frank , Radice, Antonella , Sinico, Renato Alberto , Terrier, Benjamin , Tzioufas, Athanasios G. , Jennette, J Charles , Jayne, David , Bossuyt, Xavier , Hellmich, Bernhard , Mohammad, Aladdin J , Novikov, Pavel I , Pagnoux, Christian , Sada, Ken‐ei , Segelmark, Mårten , Shoenfeld, Yehuda , Specks, Ulrich , Vaglio, Augusto , Zhao, Ming‐Hui , Tervaert, Jan Willem Cohen

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 25, 2020 | Volume: 202 | Issue: 10 | Pages: 1360-1372

10.1164/rccm.202005-1628so | PMID 32584187 Get It

Abstract An international consensus on antineutrophil cytoplasm antibodies (ANCA) testing in eosinophilic granulomatosis with polyangiitis (EGPA) is presented. ANCA, specific for myeloperoxidase (MPO), can be detected in 30–35% of patients with EGPA. MPO-ANCA should be tested with antigen-specific immunoassays in any patient with eosinophilic asthma and clinical features suggesting EGPA, including constitutional symptoms; purpura; polyneuropathy; unexplained heart, gastrointestinal, or kidney disease; and/or pulmonary infiltrates or hemorrhage. A positive MPO-ANCA result contributes to the diagnostic workup for EGPA. Patients with MPO-ANCA–associated EGPA have vasculitis features, such as glomerulonephritis, neuropathy, and skin manifestations, more frequently than patients with ANCA-negative EGPA. However, the presence of MPO-ANCA is neither sensitive nor specific enough to identify whether a patient should be subclassified as having “vasculitic” or “eosinophilic” EGPA. At present, ANCA status cannot guide treatment decisions, that is, whether cyclophosphamide, rituximab, or mepolizumab should be added to conventional glucocorticoid treatment. In EGPA, monitoring of ANCA is only useful when MPO-ANCA was tested positive at disease onset.
Primary Hyperparathyroidism in Pediatric Patients
Kollars, Josh, Zarroug, Abdalla E., Heerden, Jon van, Lteif, Aida, Stavlo, Penny, Suarez, Luis , Moir, Christopher R. , Ishitani, Michael B., Rodeberg, David A. , Kollars, Joshua P.

Mayo Clinic

Pediatrics | April 1, 2005 | Volume: 115 | Issue: 4 | Pages: 974-980

10.1542/peds.2004-0804 | PMID 15805373 Get It

Objective. Primary hyperparathyroidism (HPT) is unusual in children. We reviewed our experience with HPT to better characterize these children. Methods. The retrospective review of patients <19 years old who underwent parathyroid resection for primary HPT from 1970 to 2000 was performed at a single institution.. Results. Fifty-two patients were identified. Median age was 16.8 years (range: 4–18.9) with a female-to-male ratio of 3:2. Eighty-five percent had an elevated parathyroid hormone (PTH) level, and 15% had an inappropriately normal PTH level during hypercalcemia. Serum calcium was elevated in all patients except for 2 with multiple endocrine neoplasma (MEN)-IIA and 1 with familial non-MEN HPT, but both had elevated PTH levels. Alkaline phosphatase levels were significantly higher in children with documented bone involvement. At presentation 41 patients (79%) were symptomatic and end-organ damage (nephrocalcinosis, nephrolithiasis, acute pancreatitis, or bone involvement) occurred in 23 patients (44%). Thirty-four patients (65%) had a single adenoma; hyperplasia was identified in 16 patients (27%), and of these cases, 57% occurred in patients diagnosed with MEN-I. Short-term complications included transient hypocalcemia in 29 patients (56%) and transient vocal cord paralysis in 2 patients (4%). Long-term complications were significant for permanent hypocalcemia in 2 patients (4%) and no recurrent laryngeal nerve injuries. No parathyroid abnormalities were identified during exploration in 4 (8%) children. Long-term follow-up was achieved in 98% of patients for a mean and median of 13 years. Resolution of hypercalcemia was achieved in 94% of cases. Conclusion. The diagnosis of primary HPT in pediatric patients is frequently delayed, is commonly symptomatic, and has significant morbidity. For children in whom HPT is suspected, evaluation of serum calcium and PTH levels is diagnostic in 100% of children. Parathyroid resection is effective at restoring normal serum calcium, has few complications, and is the treatment of choice for children with primary hyperparathyroidism.